191
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
Condition(s):Alcoholic Liver DiseaseLast Updated:May 5, 2021Recruiting
Monoclonal Antibody: 6773 Clinical Trials, Page 20 of 678
Hide Studies Not Open or Pending
192
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
Condition(s):HCV Infection; Liver TransplantationLast Updated:June 14, 2016Terminated
193
A Phase I/II Study of TJ004309 for Advanced Solid Tumor
Condition(s):Advanced Solid TumorLast Updated:April 15, 2022Recruiting
194
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
Condition(s):Colorectal NeoplasmsLast Updated:May 10, 2022Recruiting
195
Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer
Condition(s):Colorectal CancerLast Updated:January 16, 2013Completed
196
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Condition(s):Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Refractory T-Cell Non-Hodgkin LymphomaLast Updated:August 4, 2020Completed
197
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Condition(s):Healthy Adult Immune Responses to VaccineLast Updated:October 26, 2020Completed
198
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Condition(s):Myelofibrosis; Primary Myelofibrosis; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Post-essential Thrombocythemia Related MyelofibrosisLast Updated:December 8, 2014Terminated
199
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Condition(s):Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:January 16, 2014Withdrawn
200
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Condition(s):Solid Tumor, AdultLast Updated:November 15, 2021Active, not recruiting